Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
OBX Catalyst Timeline
Dated clinical, regulatory and corporate events for Obsidian Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Obsidian Therapeutics, Inc.
Upcoming catalysts 2
Event history 15
Past FDA Catalysts and PDUFA Decisions
How OBX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-07 | amsokigene autoleucel (amsoki-cel, formerly OBX-115) | Phase 1/2 data presentation | Phase 1/2 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OBX-115 Cell TherapiesNCT06060613 | Tumor Skin | Phase 1/2 | RECRUITING | 254 | Jun 30, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every OBX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| amsoki-cel | advanced melanoma | Phase 1/2 | 2026-11-12 | objective response rate: 67%; median progression free survival: 8.3 months; median duration of response: not yet reached; median study follow up: 14.3 monthsRead More | Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business UpdatesRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in OBX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in OBX for Q2 2026. | ||||
Ownership Trends
OBX Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How OBX ranks across every disease it competes in
OBX News
Obsidian Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
Obsidian Therapeutics reported positive updates on amsoki-cel for advanced melanoma, showing a 67% objective response rate and a median progression-free survival of 8.3 months. The company is currently enrolling patients in a registration-enabling cohort of the Phase 1/2 Agni-01 study, with topline data expected by the end of 2027. Additionally, Obsidian has a strong cash position of $324.4 million.
Read more →Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting
Obsidian Therapeutics reported positive results for amsoki-cel in advanced melanoma. The therapy achieved a 67% objective response rate, with significant durability of responses. Safety data showed no dose-limiting toxicities. Updated data will be presented at the SITC 2026 Annual Meeting, with further results expected by year-end 2027.
Read more →Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Obsidian Therapeutics has announced a poster presentation of updated data on amsoki-cel for patients with immune-checkpoint inhibitor-resistant advanced melanoma. This data is derived from both a Phase 1 single-center first-in-human study and a Phase 1/2 multicenter study. The presentation will take place at the SITC 2026 Annual Meeting.
Read more →Obsidian Therapeutics Announces First Patient Enrolled in the Registration-enabling Cohort of Phase 1/2 Agni-01 Study Evaluating Amsoki-cel (OBX-115) in Advanced Melanoma
Obsidian Therapeutics has successfully enrolled the first patient in the registration-enabling cohort of its Phase 1/2 Agni-01 study. This study evaluates amsoki-cel, an engineered tumor-infiltrating lymphocyte therapy, for treating advanced melanoma. The enrollment marks a crucial step towards potential regulatory approval for this innovative treatment.
Read more →Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million
Obsidian Therapeutics has completed its merger with Galera Therapeutics and raised $350 million through a private placement. The combined company will focus on advancing its engineered TIL cell therapies, particularly OBX-115, which is in clinical trials for solid tumors. The funding is expected to support operations through key clinical milestones until the second half of 2028.
Read more →Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
Obsidian Therapeutics announced promising Phase 2 results for OBX-115, an engineered TIL cell therapy for advanced melanoma. The therapy demonstrated a 67% objective response rate, including two complete responses, with a favorable safety profile. The results will be presented at the 2026 ASCO Annual Meeting, highlighting OBX-115's potential as a viable treatment option for patients with difficult-to-treat melanoma.
Read more →Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
Obsidian Therapeutics will present Phase 2 clinical data for OBX-115, an engineered TIL cell therapy, at the 2026 ASCO Annual Meeting. The study focuses on patients with advanced melanoma who have not responded to immune checkpoint inhibitors. The presentation is scheduled for June 1, 2026, and aims to highlight the therapy's potential benefits.
Read more →Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
Galera Therapeutics and Obsidian Therapeutics have announced a merger agreement to form a new company, Obsidian Therapeutics, Inc., along with a $350 million private placement financing. The merger aims to leverage Obsidian's engineered TIL cell therapies and is expected to fund operations into 2028. The transaction is anticipated to close by Q3 2026, pending stockholder approval.
Read more →Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer
Obsidian Therapeutics has appointed Julie Feder as Chief Financial Officer. With over 20 years of experience in strategic finance, Feder's expertise is expected to support the company's clinical development of OBX-115, an engineered TIL cell therapy. The appointment comes at a crucial time as the company progresses towards registration-enabling trials.
Read more →Obsidian Therapeutics Announces Positive Clinical Data from OBX-115 in Patients with Advanced Melanoma in Ongoing Multicenter Study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Obsidian Therapeutics presented positive Phase 1 clinical data for OBX-115 at the 2025 ASCO Annual Meeting. The study involved 11 patients with advanced melanoma who were resistant to immune checkpoint inhibitors. The novel therapy, which utilizes engineered TIL cells, achieved an overall response rate of 67%.
Read more →Obsidian Therapeutics to Present Preclinical Data Supporting Novel Application of cytoDRiVE® Platform at the American Society of Gene and Cell Therapy Annual Meeting
Obsidian Therapeutics announced the presentation of preclinical data from its cytoDRiVE platform at the ASGCT Annual Meeting 2025. The data showcases novel applications for regulating therapeutic proteins, including a new approach using artificial transcription factors. The lead program, OBX-115, aims to treat patients with advanced melanoma by leveraging pharmacologically regulatable IL15.
Read more →Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
Obsidian Therapeutics announced the presentation of three abstracts at the AACR Annual Meeting 2025, showcasing advancements in their engineered cell and gene therapies. Highlights include updates on the Agni-01 trial and preclinical data from the cytoDRiVE platform, which enhances IL12 expression for improved tumor control. The findings suggest potential benefits for patients with advanced solid tumors.
Read more →Obsidian Therapeutics to Present Clinical Data from OBX-115, its Engineered TIL Cell Therapy, for Patients with Advanced Melanoma in Oral Presentation at the 2025 ASCO Annual Meeting
Obsidian Therapeutics announced two presentations at the 2025 ASCO Annual Meeting, including an oral presentation of Phase 1 results from the Agni-01 study of OBX-115, an engineered TIL cell therapy for patients with ICI-resistant advanced melanoma. The presentations will take place from June 1-3, 2025, in Chicago.
Read more →